Status:
UNKNOWN
Right Ventricular Haemodynamic Evaluation and Response to Treatment
Lead Sponsor:
University of Giessen
Collaborating Sponsors:
German Research Foundation
Conditions:
Right Ventricular Dysfunction
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Mono-center Study to evaluate different multimodal functional parameter of the right ventricle in PAH-patients
Detailed Description
Mono-center-study tu evaluate functional parameters in cardiac MRI, conductance catheter (pressure-volume-loops), echocardiography and right heart catheter in PAH patients and to compare different mul...
Eligibility Criteria
Inclusion
- PH Nizza group 1 and patients without pulmonary hypertension after having the right heart catheter on clinical grounds
- ability to sign informed consent
- male and female between 18 to 85 years
- haemodynamic criteria:
- Pulmonary vascular resistance (PVR) \> 240 dyn x sec x cm-5
- Mean Pulmonary artery pressure (mPAP) ≥ 25 mmHg for PAH patients
- normal haemodynamic in controls
- therapy-naive or at least since two months stabil therapy with approved drugs for PAH (Sildenafil, Tadalafil, Macitentan, Ambrisentan, Bosentan, Iloprost, Treprostinil, Riociguat).
Exclusion
- therapy with positive inotropic drugs (dobutamin etc.)
- missing informed consent
- pregnancy or lactation
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03403868
Start Date
January 1 2016
End Date
December 1 2021
Last Update
December 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital Giessen
Giessen, Germany, 35392